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Exploring the Role of Rheumatic 




Non-communicable diseases (NCDs) frequently aggregate due to shared patho-
physiological mechanisms, either as sequential steps in the same causal pathway or 
as common results of the same exposures, leading to a high prevalence of disease 
co-occurrence, a phenomenon known as multimorbidity. Multimorbidity is a 
patient-centered concept where all morbidities are regarded of equal importance 
irrespective of whether they started before or after any other disease in question. 
Rheumatic and musculoskeletal diseases (RMDs) are among the most prevalent 
groups of NCDs, and probably due to their high incidence and low case fatality, they 
are highly susceptible to multimorbidity. Complex patients, such as some of those 
with multimorbidity, are nowadays the norm, implying a growing concern that 
clinical practice guidelines fail to adequately address the care of complex patients. 
The ramifications of suffering from multimorbidity unfold for each patient, within 
their social, educational, cultural, behavioral, economic, and environmental 
contexts, which in turn affect disease management.
Keywords: rheumatic and musculoskeletal diseases, non-communicable diseases, 
multimorbidity, patient-centered care
1. Introduction
Multimorbidity is the concurrent presence of more than one chronic disease [1] 
in the same person and affects a substantial part of the adult population. Although 
the medical education and medical research are focused mainly on individual 
diseases, the study of multimorbidity is increasingly common. A recent bibliomet-
ric study revealed that the number of publications regarding this topic increased 
60% after 2010 [2]. Nevertheless, the study of multimorbidity is still not sufficient 
to reduce the gap between the available evidence for single condition vs. multiple 
conditions [2].
Multimorbidity is a relatively new concept and a challenging area in clinical 
practice globally, and some confusion persists regarding its definition. For instance, 
the terminologies multimorbidity and comorbidity have been used interchange-
ably despite their differences. Comorbidity, as originally described by Feinstein 
in 1970 [3], is used to describe any clinical entity coexisting with an index disease 
under study. This term and its definition are widely accepted and used. However, 
the definition of multimorbidity, which is the term most frequently used when no 
index disease is designated, is still not consensual. Indeed, only in 2018, the term 
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multimorbidity was accepted as a Medical Subject Heading (MeSH) by the United 
States National Library of Medicine and with the simple definition “the complex 
interactions of several co-existing diseases”. Despite this somehow insufficient 
definition, it is usually accepted that multimorbidity takes into account chronic or 
long-term diseases or conditions, including both physical and mental diseases, with 
none considered the index disease [4].
Despite the stated differences, the concepts of comorbidity and multimorbid-
ity are not mutually exclusive or contradictory, but consider a patient with more 
than one disease at the same time from different perspectives. While comorbidity 
considers any additional disease as consequence, complication, or coincidence, 
multimorbidity is a more generic, patient-centered concept, where all morbidities 
are regarded of equal importance irrespective of whether they started before or 
after any other disease in question, and that contemplates all aspects of a patient’s 
condition, including potential disease interactions and potential pathophysiological 
links [5]. Multimorbidity considers that the pathophysiological links between these 
diseases, syndromes, or conditions may overlap and that their management may 
interact to varying degrees.
Highly prevalent chronic diseases, such as arthritis, diabetes, chronic lower 
respiratory tract disease, or stroke, are known to co-occur frequently [6], and even 
less prevalent conditions still may occur in the same person at the same time. It 
is clear that, at the population level, diseases may aggregate due to chance alone, 
i.e., the more frequent a disease is, the more likely it is to coexist with others 
even in the absence of a direct causal relation, particularly for conditions which 
become more common with increasing age. However, non-communicable diseases 
(NCDs) also frequently aggregate due to shared pathophysiological mechanisms, 
either as sequential steps in the same causal pathway (causal multimorbidity) or 
as common results of the same exposures (associative multimorbidity) [7]. One 
example is a known causal pathway between rheumatoid arthritis and cardiovas-
cular disease [8]. Another example is the increased risk of both osteoarthritis and 
type 2 diabetes in people with obesity, a shared risk factor between several NCDs 
that consequently increases the likelihood of these diseases clustering in the same 
subject [9]. This framework provides a causal or associative meaning to several 
mechanisms commonly used to explain for disease co-occurrence: general disease 
susceptibility, interaction between gene and environment, association between 
morbidities in a mutually reinforcing causal loop, effects on different organs of 
psychosocial and cultural factors, life events and coping styles, and common 
underlying pathogenic mechanisms, such as chronic inflammation [7, 10].
2. Multimorbidity burden
Multimorbidity is becoming increasingly important in research and daily clinical 
practice. Its burden to both the individual and society is increasing, probably due 
to higher life expectancy, lowered thresholds for diagnoses, advances in medical 
care, and possibly due to a true increase in the prevalence of some chronic diseases 
[11]. Despite the existence of abundant information regarding epidemiology, risk 
factors, and management of individual chronic diseases, for multimorbidity only 
a few clinical guidelines exist making informed decisions harder. For example, 
following clinical practice guidelines for individual chronic conditions, a recent 
systematic review reported that a hypothetical 78-year-old woman with five 
chronic conditions [osteoporosis, osteoarthritis, diabetes type 2, hypertension, 
and chronic obstructive pulmonary disease (COPD)] would be prescribed up to 12 
separate medications, taken at five times during the day, and should be engaged in 
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14 non-pharmacological activities [12, 13]. Given that each one of these diseases has 
different therapies, the management strategy for the patient with multimorbidity 
may be influenced by the care provided to each one of the conditions, including 
limitations of life expectancy, interactions between therapies, and/or contraindica-
tions to therapy for one condition due to other conditions [14]. Additionally, most 
times, the use of many services to manage individual diseases can become duplica-
tive and inefficient and may be burdensome and unsafe for patients because of poor 
coordination and integration. In fact, a key aspect of multimorbidity is that chronic 
diseases are likely to act synergistically [15], causing an overall burden that can be 
larger than the sum of their individual impacts.
At the patient level, multimorbidity is associated with higher mortality [16], 
worsened functional status, and poorer quality of life [17]. Additionally, people 
living with multimorbidity have greater self-care needs [18] and are especially 
likely to rely on a caregiver for health management [19]. At the healthcare level, 
it implies increased risk of receiving less than best practice care [20], more 
frequent postoperative complications [21], longer hospitalization, higher likeli-
hood of readmission [22], more frequent healthcare utilization, higher direct 
costs [23, 24], and increased use of polypharmacy with the potential for adverse 
drug effects [25]. With all these adverse health outcomes, the ramifications of 
suffering from multimorbidity affect the individual within social, educational, 
cultural, behavioral, economic, and environmental circumstances, which in turn 
affect disease management.
Studies have shown that age, household income, and family structure are the 
most important measured predictors of the multimorbidity status [26]. Moreover, 
multimorbidity tends to be more common in females than in males [26, 27]. The 
presence of multimorbidity also suggests higher risk of additional conditions, 
i.e., people with multimorbidity are at a higher risk of being diagnosed with two 
or more new diseases than those with no disease [28], probably due to increased 
interaction with healthcare professionals and higher healthcare utilization. 
Additionally, several important modifiable risk factors that are associated with 
the development of individual chronic diseases may play an important role in 
multimorbidity. These include lifestyle factors such as tobacco smoking and alcohol 
intake, over- and undernutrition, physical inactivity, and occupational exposures 
[29–32]. Many of these factors are common to multiple diseases. For instance, 
smoking increases the risk of chronic respiratory diseases, cardiovascular diseases, 
and neoplasms, while obesity increases the risk of cardiovascular diseases and mus-
culoskeletal disorders. Therefore, it is not surprising that the presence of these risk 
factors increases the risk of a particular combination of chronic diseases. A recent 
bibliometric study showed that the risk factors most commonly mentioned in 
multimorbidity studies are physical activity and obesity/high body mass index [2]. 
Additionally, a recent overview of systematic reviews summarized the evidence on 
risk factors for multimorbidity into four groups: biomedical and individual factors 
(aging, women, high number of previous diseases, negative life events, external 
health locus of control, and mental disorders), health behaviors (smoking, over-
weight, obesity, high waist to hip ratio, and low physical activity), socioeconomic 
characteristics (lower social economic status, lower education, less social networks, 
full dependency, and unemployment), and social and environmental factors (liv-
ing in urban areas in lower middle income country) [33].
Despite the increase in research outputs regarding multimorbidity, the evalu-
ation of the burden of multimorbidity and its population impact remains chal-
lenging. In the European Union, there are an estimated 50 million people with 
multimorbidity, and this number is expected to grow as the population ages [34]. 
Estimates of the prevalence of multimorbidity vary from 4.4% to over 90% [35–37], 
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a discrepancy driven by distinct study populations or data sources, usually involv-
ing differences in demographic characteristics and disease types or classification. 
Despite this, up to the present, no gold standard exists regarding how to assess mul-
timorbidity, and there is no consensus on which conditions should be considered 
or on the method used for measuring multimorbidity, which makes comparisons 
among studies difficult.
3. The role of rheumatic and musculoskeletal diseases in multimorbidity
Rheumatic and musculoskeletal diseases (RMDs) are among the most prevalent 
groups of NCDs [38]. They are strong determinants of pain [39] and disability [40] 
and the first to third largest contributors to years lived with disability (YLDs) in 
almost all world regions [41]. Additionally, they have a high impact on quality of life 
[42], complexity of medication regimens [43], and affect the ability to continue paid 
employment [44]. Due to their high incidence and low case fatality, RMDs frequently 
co-exist with other conditions [37, 45]. Despite their well-known association with a 
wide scope of adverse health outcomes [46–49], the inclusion of RMDs in multimor-
bidity research tends to be inconsistent and selective. However, evidence supports 
that RMDs appear to form a principal component of certain multimorbidity clusters 
[50] and are common in multimorbidity [51, 52], with one study reporting that even 
after adjustment for age and gender, the odds of multimorbidity were greater in 
respondents with musculoskeletal conditions than those with any of the non-muscu-
loskeletal conditions included in different definitions of multimorbidity assessed [51].
RMDs are also a highly heterogeneous group of NCDs [38], from inflammatory 
rheumatic diseases (such as rheumatoid arthritis and spondyloarthritis) to degen-
erative conditions (such as osteoarthritis), fragility conditions (such as osteoporo-
sis), or regional pain syndromes (such as low back pain, neck pain and, the chronic 
widespread pain syndrome) [53]. RMDs are common throughout the life course, 
but some become even more common at older ages, in particular osteoarthritis. 
Despite this, RMDs are not always assessed in multimorbidity studies, and when 
assessed, they are usually restricted to osteoarthritis [54] or to broadly encapsulat-
ing categories that include arthritis, other joint disorders, or other painful condi-
tions in the same category [26, 55].
It is plausible that the prevalence of multimorbidity might vary for subtypes 
of RMDs included in each definition. The subgroups with the highest prevalence 
of multimorbidity are typically osteoporosis, osteoarthritis, and inflamma-
tory arthritis [51], but it remains to be determined whether RMDs in general, or 
only particular subgroups of RMDs, are associated with increased prevalence of 
multimorbidity.
Furthermore, multimorbidity research typically focuses on older people, natu-
rally excluding generally less disabling RMDs, such as work-related musculoskeletal 
conditions. However, multimorbidity is not simply a process of aging [36], suggest-
ing that to fully capture the burden of RMDs in multimorbidity a broader age range 
should be evaluated. As a matter of fact, considering that the presence of one condi-
tion increases the risk of multimorbidity in disease-specific populations (probably 
due to shared lifestyle and biomedical disease risk factors, as well as medication use 
[56] or iatrogenic effects [57]), the study of the role of RMDs in multimorbidity 
should start at young ages to fully capture the heterogeneity of RMDs, including 
soft tissue disorders or others that start at younger working ages.
Many important risk factors for common RMDs show remarkable overlap with 
risk factors for multimorbidity. For example, age and female gender are two of the 
most important non-modifiable risk factors for some RMDs [58], and as previously 
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stated, they are also common risk factors for multimorbidity. Modifiable risk factors 
such as obesity or low physical activity are importantly associated with osteoarthritis 
and regional pain syndromes, including low back pain [59]. Additionally, smoking 
is the main modifiable risk factor for inflammatory arthritis, and smoking, poor 
nutrition, and low physical activity are lifestyle risk factors for osteoporosis [60]. All 
these risk factors have been linked to multimorbidity in recent publications [29–32].
Because of the heterogeneous multimorbidity definitions used in different stud-
ies, it is difficult to fully assess the impact of RMDs on multimorbidity. However, 
RMDs usually aggregate with a wide set of NCDs. An Australian systematic review 
of population-based studies in the elderly found that over 50% of elderly patients 
with arthritis also had hypertension followed by cardiovascular diseases, dyslipid-
emia, diabetes, and mental health problems, whereas 60% of elderly patients with 
asthma reported arthritis followed by cardiovascular diseases and diabetes [61]. 
According to several systematic reviews, arthritis or osteoarthritis is usually comor-
bid with hypertension, cardiovascular diseases, dyslipidemia, diabetes, mental 
health problems, asthma, depression, and metabolic conditions [45, 61–63].
As previously described [64–66], RMDs frequently cluster with cardiometabolic 
conditions due to common pathophysiological risk factors, such as immobility, 
obesity, and systemic inflammation [67]. Additionally, pleuropulmonary disease 
may occur in patients with systemic autoimmune rheumatic diseases due to several 
causes, including infection in the treated patient, toxic medication reactions, and 
inherent manifestations of the diseases themselves [68]. Also, studies have shown a 
slightly increased risk of specific malignancies in people with rheumatoid arthritis 
[69], possibly due to smoking as a common risk factor for rheumatoid arthritis 
and lung cancer [70] and estrogen changes, which are common to rheumatoid 
arthritis and breast cancer [71]. A strong bidirectional relation between depressive 
states and musculoskeletal symptoms, especially pain, is well documented, which 
accounts for the clustering of these conditions [72]. These findings can be inter-
preted in the light of the current discussion about inflammatory as well as oxidative 
and nitrosative stress pathways that underpin the common pathophysiology of 
depression and RMDs [73]. Additionally, inflammatory cytokines, glucocorticoid 
treatment, immobilization, and reduced physical activity due to tender joints and 
muscle weakness have shown to play a key role in favoring low bone mineral density 
in RMDs [74], especially in people with rheumatoid arthritis [75].
The specific combination of RMDs with other NCDs also seems to have a 
strongly deleterious effect in adverse health outcomes. For example, co-occurrence 
of pulmonary and cardiac diseases is most often associated with mortality, but work 
disability is more strongly associated with depression [76]. Therefore, when trying 
to assess how multimorbidity affects prognosis, we need to define which disease 
combinations we are referring to and which outcome is of greatest interest. Slater 
and colleagues [77] found that among people with diabetes, cardiovascular, and 
respiratory diseases, comorbid musculoskeletal conditions increased the risk and 
accounted for a substantial proportion of activity limitations. Also, patients with 
rheumatoid arthritis and comorbidities are less likely to achieve treatment targets 
such as remission or low disease activity [78]. Others demonstrated that multimor-
bidity and depressive symptoms are strongly linked to functional limitations and 
lower self-rated health [79], that RMDs in multimorbidity worsen daily functioning 
and quality of life [17], and that multimorbidity is associated with frequent health-
care utilization and higher costs for the healthcare system [80]. Depression seems to 
interact synergistically with arthritis and neck/back disorders to increase the odds 
of reporting chronic pain beyond an additive model [81]. Additionally, the presence 
of RMDs in the context of multimorbidity tends to amplify the risk of adverse work 
outcomes and especially of sick leave [52].
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4. The challenges of multimorbidity management
The management of patients with multimorbidity is challenging. Although it 
could be expected that people with multimorbidity might be receiving better qual-
ity of healthcare than that individuals with only one disorder, at least partly because 
of greater contact with healthcare services [82], people with multimorbidity have 
more difficulties with disintegration of care, polypharmacy, and medical error 
because much specialized care is focused on the treatment of one disease [5]. Those 
with multimorbidity frequently receive care from family physicians, other medical 
specialists, and other healthcare professionals, such as nurses or physiotherapists, 
who may not be communicating effectively with each other [83]. Additionally, and 
despite the confirmed effectiveness of many individual treatments commonly used 
in chronic conditions, each additional therapy carries an additional burden, known 
as treatment burden, which includes physical effects of treatment, financial losses, 
and the psychosocial effects of time demands and dependence on others for assis-
tance [84]. This means that people often suffer from a combination of disease and 
treatment burdens and that people receiving multiple treatments will have a higher 
treatment burden than those receiving only one treatment.
Currently, the main challenge of health professionals when targeting multi-
morbidity is to try to step aside from a disease-centered perspective, very deeply 
rooted in health professionals’ education and strongly encouraged through pay-
for-performance systems, to switch to the patient as the focus of treatment. For 
example, the typical treatment perspective for a patient with RMDs and other 
conditions focuses on the comorbidity concept, i.e., in the treatment of the index 
disease [5]. A medical doctor, usually a rheumatologist, will apply the treat-to-
target concept to induce remission of that disease [85], hoping that this treatment 
will also positively affect non-RMD comorbidities. The treat-to-target approach 
is generally defined as a proactive treatment strategy, operationalized as a precise 
treatment algorithm, in which the clinician treats the patient aggressively enough 
to reach and maintain specific goals, such as remission or low disease activity [85]. 
In contrast, when considering the multimorbidity concept, the focus is on treating 
the patient, usually trying to improve overall well-being. In multimorbidity, it is 
harder to assess treatment effectiveness, and other concepts such as quality of life, 
overall function or health, and the patients’ preferences should be also considered 
[5]. In order to help the clinicians, a recent clinical guideline suggesting a patient-
centered approach to multimorbidity was published [86, 87]. It is important to 
notice that it is very difficult to publish guidelines concerning a disease-centered 
treatment for every combination of chronic conditions, which is one of the rea-
sons why multimorbidity guidelines are more likely to take a patient-centered 
approach, targeting general well-being, quality of life, independence, autonomy, 
and improved function, but especially patient’s goals, values, and priorities [86]. 
By implementing the concept of patient-centered care in daily practice, a greater 
effectiveness of diagnosis and treatment approaches and also improved clinical 
outcomes are expected.
This new clinical guideline suggests that in patient-centered care it is impor-
tant to understand the patient’s life, establishing what is important to them, and 
acknowledge the current disease and treatment burdens. After that, a revision of 
the patient’s current medicines and other treatments should be done. The risks 
and benefits of each treatment (including non-pharmacological ones) should 
be weighted, and later, an individualized management plan, including timing of 
follow-up, should be developed and agreed upon with the patient [86]. Health 
professionals will have the most difficult task: to balance medical knowledge and 
expertise with patients’ goals, when trying to reduce the impact of any conditions 
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on the adverse health outcomes that really worry the patient. It is not only about 
attaining one disease remission but rather to achieve a “healthy” life, and this is 
even more important when the patient is chronically ill.
Patient-centered care for patients with multimorbidity can be described as 
a care which (1) is attentive to patient’s psychosocial as well as physical needs, 
(2) explores the patient’s concerns and priorities for care, (3) conveys a sense 
of partnership between the patient and physician, (4) facilitates active patient 
involvement in decision-making, and (5) is coordinated across professionals, 
facilities, and support systems [88, 89]. However, the evidence regarding the 
effectiveness of such care is still lacking. The need for such evidence, includ-
ing the need for patient care guidelines and health programs that are multiple 
disease-centered, is nowadays well established. Despite the recent publication 
of new guidelines and frameworks regarding patient-centered and integrated 
care [90, 91], the implementation of these recommendations in day-to-day work 
will require a re-organization in the way care is delivered. In a qualitative study, 
Bayliss and colleagues [18] explored the healthcare priorities of patients with 
multimorbidity. The priorities for patients were easy access to care and clini-
cians, but especially they desired healthcare providers who had a caring attitude 
and listened to them, understanding that their needs were unique and fluctuat-
ing. A recent systematic review [92] described comprehensive care programs 
targeting multimorbidity patients and estimated their effectiveness regarding 
improvement of patient- and caregiver-related outcomes, healthcare utilization, 
and costs. The authors concluded that providing comprehensive care might result 
in higher patient satisfaction, less depressive symptoms, a better health-related 
quality of life, or functioning, but also found that the evidence is still insuffi-
cient. More (good quality) studies using more appropriate outcome measures are 
needed [92].
Patient-centered care must be provided by a multidisciplinary team, and this is 
a great challenge. There must be clarity about who will be responsible for carrying 
out the different actions outlined in a plan, with appropriate support and coordi-
nation between professionals. Although it would be expected that several health 
professionals would have expertise in assessment and management of RMDs and 
differ mainly by the types of interventions they use, this is often not the case, given 
that different professionals have different curricula and often different perspec-
tives regarding diseases and treatment goals [93]. So, it should be recognized that 
an integrated approach with all the disciplines and professionals working together 
is the ideal way of achieving the best outcome for the patient. Healthcare services 
should be aware of this paradigm shift and must provide integrated coordinated 
multidisciplinary care; however, this is a multifaceted challenge that cannot be 
overcome with a single effort.
5. Conclusion
Complex patients, such as some of those with multimorbidity, are nowadays 
the norm, implying a growing concern that clinical practice guidelines fail to 
adequately address the care of complex patients. As already mentioned, the rami-
fications of suffering from multimorbidity unfold for each patient, within their 
social, educational, cultural, behavioral, economic, and environmental contexts, 
which in turn affect disease management. The healthcare system in several coun-
tries is typically guided by clinical practice guidelines that are oriented toward 
single disease [94]. This poses a challenge for primary care professionals who try 
to implement evidence from these guidelines in patients with multimorbidity. As 
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described by Duffield and colleagues [53], people with multimorbidity are often 
required to carry out numerous tasks to maintain their health. The responsibilities 
listed by the authors include managing different tablets to be taken at specific times 
of day, week, or only occasionally; keeping stock of their pills, creams, inhalers, and 
injections; requesting repeat prescriptions on time; visiting the pharmacy to collect 
items; performing non-pharmacological treatments such as physiotherapy or other 
complementary interventions; and monitoring treatment effectiveness with regular 
lab analyses, physical tests, and medical appointments [53]. The time and effort 
required to remember and attend these appointments, including travel time, may 
require an additional treatment burden placed upon the individual [84]. Having 
a RMD as part of multimorbidity makes all of these activities even more difficult. 
People with arthritis report great difficulty or inability to grasp small objects; reach 
above one’s head; sit more than 2 hours; lift or carry 10 pounds; climb a flight of 
stairs; push a heavy object; walk a 1/4 mile; stand for more than 2 hours; and stoop, 
bend, or kneel [95]. As a result of restricted mobility and function, having a RMD 
can hamper the execution of many of the tasks required in multimorbidity care, 
limiting people’s ability to manage their health.
The impact of RMDs on patients and society should be acknowledged, as they 
are mostly non-fatal conditions with great effects at older ages. Regardless of the 
multimorbidity definition applied, musculoskeletal conditions are a common com-
ponent of multimorbidity [51], and most working-age adults who met the definition 
of multimorbidity had a musculoskeletal condition [96]. This is an important find-
ing because the strategies to include and classify musculoskeletal conditions within 
multimorbidity research have been inconsistent. Policy makers and public health 
teams should be aware of the importance of musculoskeletal health. Frequently, 
osteoarthritis and osteoporosis are seen as a natural consequence of aging and back 
pain as normal in working ages. The importance of early appropriate treatment 
for many musculoskeletal conditions in order to prevent chronicity and to reduce 
disability is undervalued. Often, adherence to treatment plans is less than optimal 
since patients are typically given little information about their condition; and many 
have misconceptions about treatments [97]. However, it is important to understand 
that even if the condition itself cannot be suppressed, health professionals can 
contribute to improve the patient’s general well-being, quality of life, independence, 
autonomy, and general function.
Governments and public health teams along with healthcare stakeholders should 
take multimorbidity into account when designing, implementing, and evaluating 
public health education, programmes, and campaigns. They should identify and 
understand the needs and requirements of people living with multimorbidity (and 
with RMDs in particular) in their populations. They should also identify, prioritize, 
and target adverse health outcomes. They should acknowledge that targeting risk 
factors can potentially reduce the burden of multimorbidity in the long term. It is 
time to face multimorbidity.
In conclusion, although population aging has been a remarkable achievement 
of public health and clinical medicine, it poses great challenges that can only be 
overcome if clinicians, researchers, and policy makers are aware of the complex-
ity of multimorbidity, which needs specialization, but also a holistic approach to 
ensure that patients receive coordinated care. However, more studies on RMDs and 
multimorbidity are still needed. Further evidence may help to better understand 
reasons for poorer health in certain groups and to aid their disease management. It 
may also contribute to assess the effect of multimorbidity on long-term outcomes, 
to identify prognostic factors, to develop effective interventions, and to support 
integrated patient-centered care programmes.
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